Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

OBJECTIVE: Robust biomarker predicting efficacy of immunotherapy is limited. Circulating tumor DNA (ctDNA) sought to effectively monitor therapeutic response as well as disease progression. This study aims to investigate predictive role of ctDNA short-term dynamic change (6 weeks postimmunotherapy)...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiao, Tang, Xiaoyong, Zhu, Hui, Zhu, Dongyuan, Zhang, Xiqin, Meng, Xiangjiao, Hua, Ying, Wang, Zhongtang, Zhang, Yan, Huang, Wei, Wang, Linlin, Yuan, Shuanghu, Zhang, Pinliang, Gong, Heyi, Sun, Yulan, Zhang, Yingjie, Liu, Zengjun, Dong, Xiaomeng, Gai, Fei, Huang, Zhan, Zhu, Changbin, Guo, Jun, Wang, Zhehai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730395/
https://www.ncbi.nlm.nih.gov/pubmed/36600554
http://dx.doi.org/10.1136/jitc-2022-004952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730395/
https://www.ncbi.nlm.nih.gov/pubmed/36600554
http://dx.doi.org/10.1136/jitc-2022-004952

Ejemplares similares